E-LIB Suche - Ergebnisse für: Sa, A.

1

198P Pembrolizumab plus olaparib vs pembrolizumab plus chem..:

Cussac, A. Llombart ; Rugo, H.S. ; Robson, M.E....
ESMO Open. 9 (2024) - p. 103220 , 2024

Link: https://doi.org/10.1016/..

2

181O Interim analysis (IA) of the atezolizumab (atezo) + sa..:

Schmid, P. ; Loi, S. ; De la Cruz Merino, L....
ESMO Open. 9 (2024) - p. 103203 , 2024

Link: https://doi.org/10.1016/..

3

180O IMpassion132 double-blind randomised phase III trial o..:

Dent, R.A. ; André, F. ; Gonçalves, A....
ESMO Open. 9 (2024) - p. 103202 , 2024

Link: https://doi.org/10.1016/..

4

261TiP TROPION-Breast05: Phase (Ph) III study of datopotama..:

Schmid, P. ; Oliveira, M. ; O'Shaughnessy, J....
ESMO Open. 9 (2024) - p. 103282 , 2024

Link: https://doi.org/10.1016/..

5

Clinical and Sociodemographic Characteristics of Patients D..:

Kaya, Kadir ; An, sa
Annals of Medical Research. 31 (2024) 4 - p. 285 , 2024

Link: https://doi.org/10.5455/..

6

203P Real-world treatment patterns in patients with HER2+ u..:

Barrios, C.H. ; Lee, S.C. ; Chung, W-P....
ESMO Open. 9 (2024) - p. 103225 , 2024

Link: https://doi.org/10.1016/..

7

188P A health-related quality-of-life (HRQoL) analysis from..:

Ueno, N.T. ; Cottone, F. ; Dunton, K....
ESMO Open. 9 (2024) - p. 103210 , 2024

Link: https://doi.org/10.1016/..

8

LBA2 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT)..:

Jhaveri, K. ; Bardia, A. ; Im, S-A....
ESMO Open. 9 (2024) - p. 103479 , 2024

Link: https://doi.org/10.1016/..

9

401P Vibostolimab coformulated with pembrolizumab (vibo/pem..:

Hsu, C-H. ; Dziadziuszko, R. ; Abreo, D.A. Gomez...
Annals of Oncology. 35 (2024) - p. S163-S164 , 2024

Link: https://doi.org/10.1016/..

10

114P Fixed-dose combination of pertuzumab and trastuzumab f..:

Jackisch, C. ; Im, S-A. ; Mattar, A....
ESMO Open. 9 (2024) - p. 103102 , 2024

Link: https://doi.org/10.1016/..

11

185P Safety, tolerability, and antitumor activity of trastu..:

Anders, C. ; Loi, S. ; Hamilton, E.P....
ESMO Open. 9 (2024) - p. 103207 , 2024

Link: https://doi.org/10.1016/..

12

191MO KEYNOTE-355: Outcomes in patients who discontinued ch..:

Rugo, H.S. ; Cescon, D.W. ; Im, S-A....
ESMO Open. 8 (2023) 1 - p. 101380 , 2023

Link: https://doi.org/10.1016/..

13

EVALUATION OF CHOROIDAL THICKNESS IN ROSACEA DISEASE:

r, Arma ; An, sa
Annals of Medical Research. 30 (2023) 3 - p. 1 , 2023

Link: https://doi.org/10.5455/..

14

TCF21 gene and cardiovascular events in a coronary populati..:

Sa, D ; Mendonca, M I ; Santos, M...
European Heart Journal. 44 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

15

Differences in the clinical course, laboratory and radiolog..:

zsoy, Hilal ; nal, Serhat ; l, sa.
Annals of Medical Research. , 2023

Link: https://doi.org/10.5455/..